Key facts
- Plantibodies’s last known valuation is $5.3M (Dec 2025).
- It has raised $1.6M.
- Notable investors include Bpifrance, Endless Frontier Labs, La French Tech, Angels Santé, Key Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Plantibodies
- ·The full record, as it builds
Funding rounds
No funding rounds for Plantibodies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Plantibodies
Developer of a biotechnology platform intended to deliver orally administered biologic therapies to the gastrointestinal tract for localized disease treatment. The company's platform uses plant-based expression systems and bioencapsulation to produce antibodies, peptides, and enzymes for oral delivery to the colon, enabling patients with gastrointestinal diseases to receive localized therapeutic activity with reduced systemic exposure and treatment burden.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Employees
- 6
- Website
- plantibodies.tech/
- Ownership
- Privately Held (backing)
Plantibodies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Plantibodies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Plantibodies in its N-PORT filings yet. We sweep new filings monthly.